(Q33231742)

24 July 2017

title

Allosteric inhibitors of Bcr-abl-dependent cell proliferation (English)

1 reference

24 July 2017

1 reference

13

Nathanael S Gray

1 reference

24 July 2017

Francisco J Adrián

1

1 reference

24 July 2017

Qiang Ding

2

1 reference

24 July 2017

Taebo Sim

3

1 reference

24 July 2017

Anastasia Velentza

4

1 reference

24 July 2017

Christine Sloan

5

1 reference

24 July 2017

Yi Liu

6

1 reference

24 July 2017

Guobao Zhang

7

1 reference

24 July 2017

Wooyoung Hur

8

1 reference

24 July 2017

Sheng Ding

9

1 reference

24 July 2017

Paul Manley

10

1 reference

24 July 2017

Jürgen Mestan

11

1 reference

24 July 2017

Doriano Fabbro

12

1 reference

24 July 2017

publication date

15 January 2006

1 reference

24 July 2017

published in

Nature Chemical Biology

1 reference

24 July 2017

volume

2

1 reference

24 July 2017

issue

2

1 reference

24 July 2017

page(s)

95-102

1 reference

https://scigraph.springernature.com/pub.10.1038/nchembio760

24 July 2017

exact match

0 references

cites work

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO760

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO760

7 January 2021

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO760

7 January 2021

Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO760

7 January 2021

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO760

7 January 2021

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO760

7 January 2021

Structure-function relationships in Src family and related protein tyrosine kinases

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO760

7 January 2021

Structural basis for the autoinhibition of c-Abl tyrosine kinase

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO760

7 January 2021

Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO760

7 January 2021

Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO760

7 January 2021

Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO760

7 January 2021

Discovery of a novel Raf kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO760

7 January 2021

Design and discovery of small molecules targeting raf-1 kinase

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO760

7 January 2021

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO760

7 January 2021

Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO760

7 January 2021

Allosteric activators of glucokinase: potential role in diabetes therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO760

7 January 2021

A combinatorial scaffold approach toward kinase-directed heterocycle libraries

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO760

7 January 2021

Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO760

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO760

7 January 2021

Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO760

7 January 2021

A myristoyl/phosphotyrosine switch regulates c-Abl

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO760

7 January 2021

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO760

7 January 2021

BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO760

7 January 2021

Mechanisms and implications of imatinib resistance mutations in BCR-ABL.

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO760

7 January 2021

The conformational plasticity of protein kinases

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO760

7 January 2021

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO760

7 January 2021

Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO760

7 January 2021

Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO760

7 January 2021

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO760

7 January 2021

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO760

7 January 2021

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO760

7 January 2021

Identifiers

DOI

10.1038/NCHEMBIO760

1 reference

24 July 2017

1 reference